Skip to main content
NCBI home page
Gut logoLink to Gut
. 1992 Jan;33(1):59–64. doi: 10.1136/gut.33.1.59

Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.

B Crotty 1, P Hoang 1, H R Dalton 1, D P Jewell 1
PMCID: PMC1373866  PMID: 1740279

Abstract

Colonic epithelial cells express HLA-DR in inflammatory bowel disease. The effect of drugs used in the treatment of inflammatory bowel disease and colchicine on interferon-gamma (IFN-gamma) induced DR expression has been investigated. HT-29 cells were cultured in 25 cm2 flasks. At 48 hours interferon-gamma (0, 50, or 100 U/ml) +/- drug were added. At 120 hours the cells were stained for HLA-DR and analysed by flow cytometry. 10(-2) M 5ASA reduced DR expression induced by 50 U/ml interferon-gamma from 62 (12)% of cells (mean SD) to 29 (20)% (p less than 0.005). Corresponding figures for 10(-2) M N-acetyl 5ASA were 68 (16)% to 39 (17)% (p less than 0.05); for 10(-2) M 4ASA, 61 (4)% to 57 (4)% (p = 0.6); for 10(-2) M N-acetyl 4ASA, 60 (12)% to 35 (13)% (p less than 0.05); for 10(-2) M olsalazine, 72 (9)% to 3 (1)% (p less than 0.001); for 10(-3) M olsalazine, 72 (9)% to 16 (10)% (p less than 0.001); for 10(-6) M colchicine, 62 (13)% to 5 (3)% (p less than 0.001); and for 10(-7) M colchicine, 62 (13)% to 10 (3)%. Similar results were obtained when DR was induced by 100 U/ml of interferon-gamma except with 10(-2) M 4ASA which reduced expression from 77 (4)% to 68 (3)% (p less than 0.05). Sulphapyridine, prednisolone, indomethacin and cyclosporin A had no effect. Concurrent staining with propidium iodide showed that these results were unchanged when viable cells alone were analysed. Prior incubation of cells with drug, followed by washing, had no effect on interferon-gamma induced DR expression. 5ASA, N-acetyl 5ASA, 4ASA, N-acetyl 4ASA, olsalazine and colchicine reduce interferon-gamma induced HLA-DR expression. In inflammatory bowel disease these compounds may impair antigen presentation by the colonic epithelium.

Full text

PDF
59

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvaro-Gracia J. M., Zvaifler N. J., Firestein G. S. Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med. 1989 Sep 1;170(3):865–875. doi: 10.1084/jem.170.3.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alván G., Orme M., Bertilsson L., Ekstrand R., Palmér L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther. 1975 Sep;18(3):364–373. doi: 10.1002/cpt1975183364. [DOI] [PubMed] [Google Scholar]
  3. Barrett K. E., Tashof T. L., Metcalfe D. D. Inhibition of IgE-mediated mast cell degranulation by sulphasalazine. Eur J Pharmacol. 1985 Jan 2;107(2):279–281. doi: 10.1016/0014-2999(85)90071-8. [DOI] [PubMed] [Google Scholar]
  4. Benoist C., Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol. 1990;8:681–715. doi: 10.1146/annurev.iy.08.040190.003341. [DOI] [PubMed] [Google Scholar]
  5. Bland P. W., Warren L. G. Antigen presentation by epithelial cells of the rat small intestine. I. Kinetics, antigen specificity and blocking by anti-Ia antisera. Immunology. 1986 May;58(1):1–7. [PMC free article] [PubMed] [Google Scholar]
  6. Bland P. W., Warren L. G. Antigen presentation by epithelial cells of the rat small intestine. II. Selective induction of suppressor T cells. Immunology. 1986 May;58(1):9–14. [PMC free article] [PubMed] [Google Scholar]
  7. Bland P. MHC class II expression by the gut epithelium. Immunol Today. 1988 Jun;9(6):174–178. doi: 10.1016/0167-5699(88)91293-5. [DOI] [PubMed] [Google Scholar]
  8. Bull D. M., Bookman M. A. Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest. 1977 May;59(5):966–974. doi: 10.1172/JCI108719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chang R. J., Lee S. H. Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line. J Immunol. 1986 Nov 1;137(9):2853–2856. [PubMed] [Google Scholar]
  10. Cuvelier C., Mielants H., De Vos M., Veys E., Roels H. Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy. Gut. 1990 May;31(5):545–549. doi: 10.1136/gut.31.5.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Daar A. S., Fuggle S. V., Fabre J. W., Ting A., Morris P. J. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation. 1984 Sep;38(3):293–298. doi: 10.1097/00007890-198409000-00019. [DOI] [PubMed] [Google Scholar]
  12. Eliakim R., Karmeli F., Razin E., Rachmilewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology. 1988 Nov;95(5):1167–1172. doi: 10.1016/0016-5085(88)90346-0. [DOI] [PubMed] [Google Scholar]
  13. Gibson P. R., Jewell D. P. Sulphasalazine and derivatives, natural killer activity and ulcerative colitis. Clin Sci (Lond) 1985 Aug;69(2):177–184. doi: 10.1042/cs0690177. [DOI] [PubMed] [Google Scholar]
  14. Guagliardi L. E., Koppelman B., Blum J. S., Marks M. S., Cresswell P., Brodsky F. M. Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. Nature. 1990 Jan 11;343(6254):133–139. doi: 10.1038/343133a0. [DOI] [PubMed] [Google Scholar]
  15. Hawkey C. J., Lo Casto M. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut. 1983 Mar;24(3):213–217. doi: 10.1136/gut.24.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ireland A., Jewell D. P. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci (Lond) 1990 Feb;78(2):119–125. doi: 10.1042/cs0780119. [DOI] [PubMed] [Google Scholar]
  17. Kaiserlian D., Vidal K., Revillard J. P. Murine enterocytes can present soluble antigen to specific class II-restricted CD4+ T cells. Eur J Immunol. 1989 Aug;19(8):1513–1516. doi: 10.1002/eji.1830190827. [DOI] [PubMed] [Google Scholar]
  18. Kvale D., Brandtzaeg P., Løvhaug D. Up-regulation of the expression of secretory component and HLA molecules in a human colonic cell line by tumour necrosis factor-alpha and gamma interferon. Scand J Immunol. 1988 Sep;28(3):351–357. doi: 10.1111/j.1365-3083.1988.tb01460.x. [DOI] [PubMed] [Google Scholar]
  19. Langer J. A., Pestka S. Interferon receptors. Immunol Today. 1988 Dec;9(12):393–400. doi: 10.1016/0167-5699(88)91241-8. [DOI] [PubMed] [Google Scholar]
  20. Lauritsen K., Hansen J., Ryde M., Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology. 1984 Jun;86(6):1496–1500. [PubMed] [Google Scholar]
  21. Leszczynski D. Interleukin-1 alpha inhibits the effects of gamma-interferon and tumor necrosis factor alpha on the expression of the major histocompatibility antigens by the rat endothelium. Am J Pathol. 1990 Jan;136(1):229–237. [PMC free article] [PubMed] [Google Scholar]
  22. MacDermott R. P., Schloemann S. R., Bertovich M. J., Nash G. S., Peters M., Stenson W. F. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989 Feb;96(2 Pt 1):442–448. doi: 10.1016/0016-5085(89)91569-2. [DOI] [PubMed] [Google Scholar]
  23. Malkinson F. D. Colchicine. New uses of an old, old drug. Arch Dermatol. 1982 Jul;118(7):453–457. doi: 10.1001/archderm.118.7.453. [DOI] [PubMed] [Google Scholar]
  24. Mason D. W., Dallman M., Barclay A. N. Graft-versus-host disease induces expression of Ia antigen in rat epidermal cells and gut epithelium. Nature. 1981 Sep 10;293(5828):150–151. doi: 10.1038/293150a0. [DOI] [PubMed] [Google Scholar]
  25. Mayer L., Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990 Oct;86(4):1255–1260. doi: 10.1172/JCI114832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mayer L., Shlien R. Evidence for function of Ia molecules on gut epithelial cells in man. J Exp Med. 1987 Nov 1;166(5):1471–1483. doi: 10.1084/jem.166.5.1471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McDonald G. B., Jewell D. P. Class II antigen (HLA-DR) expression by intestinal epithelial cells in inflammatory diseases of colon. J Clin Pathol. 1987 Mar;40(3):312–317. doi: 10.1136/jcp.40.3.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Mekori Y. A., Chowers Y., Ducker I., Klajman A. Inhibition of delayed hypersensitivity reactions by colchicine. II. Colchicine inhibits interferon-gamma induced expression of HLA-DR on gut epithelial cell line. Clin Exp Immunol. 1989 Nov;78(2):230–232. [PMC free article] [PubMed] [Google Scholar]
  29. Pickup M. E. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979 Mar-Apr;4(2):111–128. doi: 10.2165/00003088-197904020-00004. [DOI] [PubMed] [Google Scholar]
  30. Qin O. Y., el-Youssef M., Yen-Lieberman B., Sapatnekar W., Youngman K. R., Kusugami K., Fiocchi C. Expression of HLA-DR antigens in inflammatory bowel disease mucosa: role of intestinal lamina propria mononuclear cell-derived interferon gamma. Dig Dis Sci. 1988 Dec;33(12):1528–1536. doi: 10.1007/BF01535942. [DOI] [PubMed] [Google Scholar]
  31. Rasmussen S. N., Bondesen S., Hvidberg E. F., Hansen S. H., Binder V., Halskov S., Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982 Nov;83(5):1062–1070. [PubMed] [Google Scholar]
  32. Scott H., Brandtzaeg P., Solheim B. G., Thorsby E. Relation between HLA-DR-like antigens and secretory component (SC) in jejunal epithelium of patients with coeliac disease or dermatitis herpetiformis. Clin Exp Immunol. 1981 May;44(2):233–238. [PMC free article] [PubMed] [Google Scholar]
  33. Scott H., Sollid L. M., Fausa O., Brandtzaeg P., Thorsby E. Expression of major histocompatibility complex class II subregion products by jejunal epithelium in patients with coeliac disease. Scand J Immunol. 1987 Nov;26(5):563–571. doi: 10.1111/j.1365-3083.1987.tb02290.x. [DOI] [PubMed] [Google Scholar]
  34. Selby W. S., Janossy G., Mason D. Y., Jewell D. P. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol. 1983 Sep;53(3):614–618. [PMC free article] [PubMed] [Google Scholar]
  35. Spencer J., Finn T., Isaacson P. G. Expression of HLA-DR antigens on epithelium associated with lymphoid tissue in the human gastrointestinal tract. Gut. 1986 Feb;27(2):153–157. doi: 10.1136/gut.27.2.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stenson W. F., Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982 Feb;69(2):494–497. doi: 10.1172/JCI110474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Stenson W. F., Mehta J., Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol. 1984 Feb 1;33(3):407–412. doi: 10.1016/0006-2952(84)90233-8. [DOI] [PubMed] [Google Scholar]
  38. Thorsby E. Structure and function of HLA molecules. Transplant Proc. 1987 Feb;19(1 Pt 1):29–35. [PubMed] [Google Scholar]
  39. Valnes K., Huitfeldt H. S., Brandtzaeg P. Relation between T cell number and epithelial HLA class II expression quantified by image analysis in normal and inflamed human gastric mucosa. Gut. 1990 Jun;31(6):647–652. doi: 10.1136/gut.31.6.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wallace S. L., Omokoku B., Ertel N. H. Colchicine plasma levels. Implications as to pharmacology and mechanism of action. Am J Med. 1970 Apr;48(4):443–448. doi: 10.1016/0002-9343(70)90043-4. [DOI] [PubMed] [Google Scholar]
  41. Willoughby C. P., Piris J., Truelove S. C. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol. 1980;15(6):715–719. doi: 10.3109/00365528009181520. [DOI] [PubMed] [Google Scholar]
  42. van Hogezand R. A. Pharmacokinetics of olsalazine and its metabolites. Scand J Gastroenterol Suppl. 1988;148:17–20. doi: 10.3109/00365528809101541. [DOI] [PubMed] [Google Scholar]
  43. van Hogezand R. A., van Hees P. A., van Gorp J. P., van Lier H. J., Bakker J. H., Wesseling P., van Haelst U. J., van Tongeren J. H. Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis. Aliment Pharmacol Ther. 1988 Feb;2(1):33–40. doi: 10.1111/j.1365-2036.1988.tb00668.x. [DOI] [PubMed] [Google Scholar]
  44. von Ritter C., Grisham M. B., Granger D. N. Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucyl-phenylalanine-induced mucosal injury in rat ileum. Gastroenterology. 1989 Mar;96(3):811–816. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES